| Nominee | Forecast | Background |
|---|---|---|
Not independent | WATCH Prior 96.8% 70808793100 | Co-founder and Co-Chairman of Carlyle since 1987, contributing to its growth and strategic direction. |
Not independent | WATCH Prior 97.4% 70808793100 | Co-founder and Co-Chairman of Carlyle since 1987, instrumental in the firm's growth and strategic direction. |
Not independent | WATCH Prior 97.5% 70808793100 | Co-founder and Chairman Emeritus of Carlyle, integral to its growth since 1987. |
Not independent | HEALTHY Prior 98.8% 70808793100 | Chief Executive Officer and Director since 2023, with extensive leadership experience at global financial institutions. |
Afsaneh Beschloss Independent | WATCH First-time at this board · prior vote history at other boards | |
Independent | WATCH Prior 98.8% 70808793100 | Senior partner at EY with extensive experience in private equity, financial services, and health care industries. |
Independent | ELEVATED Prior 94.8% 70808793100 | Linda H. Filler has served as a lead independent director at large, global businesses. |
Independent | MATERIAL Prior 93.7% 70808793100 | Fitt has an extensive financial services background with a distinguished career at Goldman Sachs in investment banking and risk analysis. |
Not independent | ELEVATED Prior 93.7% 70808793100 | Former Chief Financial Officer of Bank of America Corporation and Operating Executive at Carlyle. |
Independent | ELEVATED Prior 98.1% 70808793100 | Mark S. Ordan has served as CEO of multiple companies and is currently the Lead Independent Director since 2022. |
Independent | ELEVATED Prior 95.3% 70808793100 | Derica W. Rice has extensive experience in global business operations and financial matters from his career at CVS Health and Eli Lilly and Company. |
Independent | WATCH Prior 94.6% 70808793100 | William J. Shaw has extensive financial and management experience from senior leadership roles at Marriott. |
Independent | ELEVATED Prior 95.3% 70808793100 | Welters founded AmeriChoice, which was acquired by UnitedHealth Group in 2002, and served as Senior Adviser to the Office of the CEO until retiring in 2016. |
| #1 | Election of Directors Filed by the board · Board recommends For Election of 13 director nominees named in the proxy statement to serve one‑year terms until the next annual meeting. |
| #2 | Ratification of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for 2026 Filed by the board · Board recommends For Ratify the Audit Committee’s selection of Ernst & Young LLP as Carlyle’s independent registered public accounting firm for fiscal year 2026. |
| #3 | Approval of The Carlyle Group Inc. Amended and Restated 2012 Equity Incentive Plan Filed by the board · Board recommends For Approve the Amended and Restated 2012 Equity Incentive Plan to increase the share reserve by 19,000,000 shares, extend the plan term, and allow recycling of withheld shares for tax withholding. Detail ›This management proposal seeks shareholder approval for an amendment and restatement of the existing 2012 Equity Incentive Plan, primarily to increase the authorized share reserve by 19 million shares (from 58.8 million to 77.8 million), extend the plan term to , and permit recycling of withheld shares used for tax withholding (excluding options and SARs). Management and the Compensation Committee justify the request by saying additional capacity is necessary to continue granting equity awards that align employee incentives with shareholder interests, to retain and incentivize senior personnel and support Firm strategic objectives and multi-year targets through 2028. The proposal outlines plan mechanics including counting rules for share usage, minimum vesting requirements (one year vesting cliff for most awards with limited exceptions), per-participant and non-employee director limits, and detailed adjustment and change-in-control provisions. The plan contains customary tax and administrative provisions (including compliance with Section 409A) and describes the Company’s existing equity program usage, the number of outstanding RSUs and PSUs, and projected available shares post-approval. The Board recommends a “FOR” vote emphasizing careful monitoring of dilution, linking awards to performance via PSUs and retention via time-vesting RSUs, and plans to manage share usage alongside its $2 billion repurchase program. Key risks include shareholder dilution and the potential for large equity grants to executives, but management points to historical and prospective practices (bonus deferral, clawbacks, stock ownership guidelines, and retention/vesting constraints) intended to mitigate those concerns. |
| #4 | Non-Binding Vote to Approve Named Executive Officer Compensation (“Say-on-Pay” Filed by the board · Board recommends For Advisory, non-binding vote to approve the compensation of the named executive officers as disclosed in the proxy statement. Detail ›This advisory management proposal asks shareholders to approve, on a non-binding basis, the compensation paid to the named executive officers as disclosed in the proxy statement, including the CD&A and compensation tables. The Board and Compensation Committee promote a pay-for-performance philosophy, with significant equity-based compensation (RSUs, PSUs, bonus deferral, and carried interest arrangements) tying management incentives to long-term firm performance. The CD&A describes program elements including the CEO’s sign-on PSUs with absolute stock price and relative TSR hurdles, the Stock Price Appreciation PSU Program for other NEOs, execution of a Bonus Deferral Program to increase RSU deferrals, executive stock ownership guidelines, clawback policies, and restrictions on hedging/pledging. Management argues that recent strong TSR (119% 3-year) and record 2025 financial results support the program’s efficacy and alignment. The recommendation to vote FOR is accompanied by a commitment to consider shareholder feedback in future compensation decisions; however, risks include potential dilution from equity awards and complexity of incentive structures which some shareholders may view skeptically. |
| Holder | % of shares | Position value |
|---|---|---|
| Capital World Investors | 4.95% | $863M |
| HARRIS ASSOCIATES L P | 4.51% | $786M |
| BlackRock, Inc. | 3.79% | $661M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.28% | $572M |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.17% | $551M |
| STATE STREET CORP | 2.69% | $468M |
| BlackRock, Inc. | 2.31% | $402M |
| MILLENNIUM MANAGEMENT LLC | 1.89% | $329M |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.75% | $305M |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 1.65% | $287M |
| Quarterly report (10-Q) | View › | |
| Definitive proxy (DEF 14A) | View › | |
| Annual report (10-K) | View › | |
| Quarterly report (10-Q) | View › | |
| Quarterly report (10-Q) | View › | |
| Definitive proxy (DEF 14A) | View › |
About the risk forecast
The risk forecast scores each director on the company’s slate against Boardroom Alpha’s YoY Director-Vote Forecast model — three XGBoost classifiers that estimate the probability the director’s vote support falls below 70%, 80%, and 90% at the upcoming annual meeting, augmented by a five-rule governance escalation layer (overboarding, audit-committee composition, prior dissent, and others).
Bands map to those probability thresholds:
- Crisis — high probability of vote support below 70%. Rare.
- Material — high probability of below 80%. The primary screening threshold.
- Elevated — significant elevated risk of dissent.
- Watch — even a mild withhold is detectable. Informational.
- Healthy — no signal of meaningful dissent.
Prior is the director’s most-recent vote-support percentage at this same board. Direction compares the forecast to that prior vote: ↑ expected better means more support than last year; ↓ expected worse means less.
Forecast applies only to non-contested annual proxies (DEF 14A). Contested situations are tracked separately on the contested-proxy pipeline. The model is retrained nightly; bands shown reflect the most recent run.
« Back to Shareholder Meeting Calendar
Frequently Asked Questions
Last updated: